EUCTR2006-004545-42-LV进行中（未招募）不适用
A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathy
TROPHOS0 个研究点目标入组 180 人开始时间: 2007年9月12日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Be a male >18 years or a post-menopausal female (>60 years of age and at least 1 year of amenorrhea).
- •2.Have painful diabetic neuropathy of >6 months duration and are either pain treatment naive or have important side effects or inadequate relief from their current pain medication.
- •3.Be on current pain medication (prescribed analgesics), stable for at least 3 months before study entry (± 25% dosage of basic pain medication, top-up rescue medication allowed), or pain treatment naive.
- •4.Have stable diabetes, defined as HbA1c <10%, no changes in medication in the previous 3 months, and no new symptoms associated with diabetes in the previous 3 months.
- •5.Have scored >2 points on the Michigan Neuropathy Screening Instrument (MNSI), part B-physical assessment by health professional.
- •6.Have an electrocardiogram (ECG) without any clinically significant abnormality.
- •The following inclusion criteria should be ascertained at the baseline visit:
- •7.Have measurable pain perception (previous 24h) on the Likert numerical rating scale with a mean =4.0 points calculated from at least 4 daily measurements over the 7 days immediately prior to the Baseline Visit.
- •8.Have stopped current pain medication at least 14 days prior to the Baseline Visit (except rescue medication).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Be pregnant female, lactating female, or female of child bearing potential (=60 years of age).
- •2.Have a documented neuropathy of any cause other than those mentioned in the inclusion criteria which might interfere with the assessment of the severity of pain (eg, including, but not limited to, alcoholic, uremic, B12, TSH, chemotherapy, HIV, post surgical, or post-traumatic neuropathy).
- •3.Have other neurological diseases that may produce weakness, sensory loss, or autonomic symptoms, or laboratory test abnormality.
- •4.Have been on pain treatment with strong opioids, more than
- •4 different drug regimens in the previous year, or a current combination of more than 2 drugs.
- •5.Have a current medication of lipid lowering agents other than statins.
- •6.Have a body mass index (BMI) >40 kg/m2 (obesity grade III).
- •7.Had any surgery within the previous 2 months.
- •8.Have concurrent serious neurological disease (eg, dementia, multiple sclerosis, or any other disease that would impact the ability of the patient to provide consent for study participation).
- •9.Have a recent history (within the previous 6 months) or current evidence of alcohol or drug abuse.
- •10.Have concurrent unstable disease involving any system (eg, advanced carcinoma, myocardial infarction, clinical or ECG signs of myocardial ischemia, cardiac insufficiency i.e. =NYHA functional classification class 2, anginal symptoms, current symptoms of CAD, renal impairment (see excl. criterion 16), or any other condition that in the opinion of the Investigator would make the patient unsuitable for study participation).
- •11.Participated in any other investigational drug or therapy study within the previous 3 months.
- •12.Changed or interrupted current well-tolerated medication during the previous 3 months.
- •13.Lack of ability or willingness to give informed consent.
- •14.Be possibly dependent on the Investigator or the Sponsor (eg, including, but not limited to, affiliated employee).
- •15.Have hemostasis disorders or a current treatment of anticoagulants.
- •16.Have non-adequate renal and/or hepatic function as follows:
- •Renal – blood creatinine >1.5 × upper limit of normal (ULN)
- •Hepatic – liver enzymes (ALT and AST) >2 × ULN
- •17.Have a known history of or current cardiac dysrhythmias and / or a known history of or current cardiovascular disease including myocardial infarction except patients with well controlled hypertension only.
- •18.Are not able to comply with regard to the known contraindications, warnings and precautions, drug-interactions and dosing recommendations of paracetamol.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathyEUCTR2006-004545-42-DETROPHOS180
进行中（未招募）
不适用
A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant - AMACEThe study objective is to assess the efficacy and safety of the Bradykinin-2 (BK-2) receptor antagonist Icatibant compared to a historic group of 47 patients with ACE inhibitor induced angioedema which we have been previously treated in our centers with current standard” therapy (250 mg methylprednisolon and 2 mg clemastine).EUCTR2009-015410-22-DEMedizinische Fakultaet der Technischen Universitaet Muenchen30
进行中（未招募）
不适用
A study of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with rheumatoid arthritis with inadequate response to prior treatment with methotrexate and low disease activity with the combination de RoActemra/Actemra y methotrexate.MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-001626-15-ESRoche Farma, S.A.
进行中（未招募）
不适用
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 (ASTRID – Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics). - ASTRIDEUCTR2004-000703-18-ESSOLVAY PHARMACEUTICALS GMBH440
进行中（未招募）
不适用
A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2. ASTRID Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril in type 2 Diabetics .essential hypertensionMedDRA version: 6.1Level: PTClassification code 10015488EUCTR2004-000703-18-ITSOLVAY PHARMA440